Kathleen N. Moore, MD, discusses the need for individualized therapies, particularly for patients with nondeficient mismatch repair endometrial cancer, highlighting the molecular heterogeneity of this category.
Dr Debra Richardson's presentation on the SIENDO study demonstrated the potential benefit of selinexor maintenance therapy in TP53 wild-type populations, with ongoing trials like XPORT-EC-042 aiming to refine this treatment approach. The meeting underscored the importance of precise molecular subgroup classification and validated predictive biomarkers to guide future therapy selection.
